The entity cluster converges on a central clinical problem: the liver as both a primary and, overwhelmingly, a secondary (metastatic) cancer site—from colorectal, pancreatic, and non-small cell lung cancer—demanding better detection, monitoring, and treatment strategies within its uniquely immunotolerant, vascularized microenvironment. Two parallel trend lines dominate. First, a diagnostic/monitoring trajectory built on circulating tumor DNA (ctDNA) and liquid biopsies, positioned as non-invasive alternatives to imaging (dynamic contrast-enhanced CT) and biopsy for addressing the persistent problem of late detection. ctDNA is paired with next-generation sequencing to assess tumor mutational burden, is used pre- and post-surgically (e.g., in resectable colorectal liver metastases patients) to stratify recurrence-free survival, and—via methylation-guided surveillance—can detect recurrence months earlier than standard CT. Complementary blood-based biomarkers (AFP, PIVKA-II) and antibody-feature prediction models (AUC ~0.52–0.79) round out a multimodal surveillance architecture aimed at at-risk populations, reinforcing calls from expert consensus meetings for structured surveillance programs.
Second, a therapeutic trajectory targeting the immunosuppressive tumor microenvironment that shields hepatic metastases from immune clearance. The PFSUV-IMQ nanoparticle system exemplifies this: a phospholipid-free small unilamellar vesicle (cholesterol/Tween80-based) delivering imiquimod, a TLR7 agonist, to hepatocytes. This platform triggers innate immune activation, sustains hepatic interferon-alpha, expands CD86+/MHC-II+ dendritic cells and IFN-γ+ CD8+ T cells, and induces tumor apoptosis—synergizing with oxaliplatin chemotherapy in CT26 and HCA-1 liver metastasis models to reduce both hepatic and lung metastatic burden. This mirrors broader efforts (AURKB knockdown reducing lung metastases, natural triterpenoids, CAR-T engineering) to overcome microenvironmental immune suppression through combinatorial chemoimmunotherapy rather than single-agent approaches.
Bridging these two trajectories is normothermic machine perfusion (NMP), an ex vivo platform that perfuses diseased livers via hepatic artery and portal vein to preserve hepatic tissue integrity and tumor genomic stability for up to 92 hours. Monitored via contrast-enhanced ultrasound, perfusion parameters, and blood gas analysis, NMP creates a living disease model for testing oxaliplatin/5-FU regimens and profiling ctDNA via NGS outside the constraints of xenografts—positioning it as a translational bridge between liquid-biopsy diagnostics and immune-modulatory therapeutics. Collectively, the cluster reflects a macro trend toward integrating minimally invasive molecular surveillance with locally delivered immune-activating nanotherapeutics, unified by ex vivo perfusion models that recapitulate the liver's tumor microenvironment for preclinical validation.